Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis
Phytomedicine · 2026
DOI: 10.1016/j.phymed.2026.158205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Wentong Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004,…. Hauptthemen laut MEDLINE: Depsides, Carcinoma, Non-Small-Cell Lung, Cinnamates, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Jiangxi University of Traditional Chinese Medicine, Shenzhen Medical Information Institute.
Abstract (Originalsprache)
BACKGROUND: Non-small cell lung cancer (NSCLC) remains a significant health challenge, and the KRAS mutation plays a critical role in its development, especially KRASG12C. Rosmarinic acid (RA), a natural polyphenolic compound, has demonstrated robust anti-cancer activities. However, the precise molecular mechanisms underlying its anti-tumor effects in NSCLC remain poorly understood. METHODS: We assessed RA's anti-tumor effects in vitro/in vivo NSCLC models. Activity-based protein profiling (ABPP) coupled with bioorthogonal click chemistry identified RA's direct molecular targets. Western blot and other techniques analyzed KRAS/AKT/ERK signaling, plus cell cycle/apoptosis molecule expression. The effect of RA on tumor suppression and the ability of tumor cells to evade macrophages in an NSCLC mouse model with KRASG12C mutation was evaluated. RESULTS: RA significantly inhibited NSCLC cell proliferation and induced apoptosis by modulating the KRAS/AKT/ERK signaling cascade. ABPP analysis revealed that RA directly binds to KRASG12C at the mutant cysteine-12 residue. Functional studies confirmed that RA-mediated cell cycle arrest and apoptosis depend on KRASG12C modulation. In KRASG12C-mutant mouse models, RA markedly suppressed tumor growth and reduced macrophage evasion by tumor cells. CONCLUSIONS: RA acts as a novel KRASG12C inhibitor that directly targets the mutant cysteine-12 residue, suppressing NSCLC progression through inhibition of the KRAS/AKT/ERK pathway and enhancement of anti-tumor immune activity. These findings highlight RA's therapeutic potential for KRASG12C-driven NSCLC and offer new insights for the development of targeted cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China; Guangdong Basic Research center of Excellence for Integrated T…
- Guangdong Basic Research center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, Guangdong provincial Key Laboratory of Chinese Medicine pharmaceutics, School of Traditional Chinese Me…
- Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
- State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
- National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330004, China. Electronic address: yangshilin@suda.edu.cn.
- Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. Electronic address: raoshuanl@smu.edu.cn.
Förderung
- Jiangxi University of Traditional Chinese Medicine
- Shenzhen Medical Information Institute
Zitieren
APA
Zhao, W., Zhang, Q., He, Y., Xing, X., An, Y., Zhang, Y., Li, W., Yang, S., Xiong, X., He, W., Wong, Y. K., Yang, S., Rao, S., Feng, Y., Luo, P., & Wang, J. (2026). Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158205
Vancouver
Zhao W, Zhang Q, He Y, Xing X, An Y, Zhang Y, et al. Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158205
BibTeX
@article{Zhao2026,
author = {Zhao, Wentong and Zhang, Qian and He, Yujing and Xing, Xuefeng and An, Yehai and Zhang, Ying and Li, Wenhui and Yang, Shiguang and Xiong, Xuan and He, Weiyi and Wong, Yin-Kwan and Yang, Shilin and Rao, Shuan and Feng, Yulin and Luo, Piao and Wang, Jigang},
title = {Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis},
journal = {Phytomedicine},
year = {2026},
doi = {10.1016/j.phymed.2026.158205}
}
EUVIMED